EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSAPEG00000013406
Gene Symbol: DHCR24
1 Cross references
209 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSAPEG00000013032
Gene Symbol: HMGCR
1 Cross references
194 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase B

Ensembl ID : ENSAPEG00000004677
Gene Symbol: HMGCRB
1 Cross references
206 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1b

Ensembl ID : ENSAPEG00000006656
Gene Symbol: PDPK1B
1 Cross references
222 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase B

Ensembl ID : ENSAPEG00000010840
Gene Symbol: HPDB
1 Cross references
207 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSAPEG00000021409
Gene Symbol: NT5E
1 Cross references
190 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSAPEG00000020431
Gene Symbol: NT5E
2 Cross references
194 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSAPEG00000019766
Gene Symbol: HTR1AB
1 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSAPEG00000001891
Gene Symbol: HTR2B
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSAPEG00000015608
Gene Symbol: HTR2CL1
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSAPEG00000016248
Gene Symbol: HTR5AB
1 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSAPEG00000005567
Gene Symbol: HTR1A
2 Cross references
104 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).